— Startup Founded by Professors from Korea’s No.1 University Advances Clinical Trials Toward Drug Approval
Founding professors of AniBiome from Seoul National University College of Veterinary Medicine
(clockwise from top left: Prof. Won-Seok Oh, Prof. Min-Soo Kim, Prof. Sung-Beom Cho, and Prof. Seung-Jun Baek)
Seoul, Republic of Korea — A biotechnology startup founded by leading veterinary professors from Seoul National University College of Veterinary Medicine, widely regarded as Korea’s leading university, has announced the launch of two adjunct therapeutic products for the management of intractable diseases in pets.
AniBiome Co., Ltd., a Korean biotech startup established by four current professors from Seoul National University’s College of Veterinary Medicine, revealed that its newly launched products—PETMUNIOME and KIDNIOME—are drawing growing attention from pet owner communities and veterinary professionals in Korea. The company emphasized that these products are not conventional supplements, but part of a long-term strategy aimed at formal therapeutic drug approval.
A Korea-Originated, Science-Driven Approach to Intractable Pet Diseases
AniBiome’s solutions are built on a multi-mechanism therapeutic support concept, simultaneously targeting the kidney, immune system, and gut—three interconnected biological axes considered critical in the management of chronic and intractable diseases in pets.
Unlike most animal health supplements currently on the market, AniBiome conducted pilot clinical trials prior to commercial release, an uncommon practice in the global pet supplement industry. Notably, results from these pilot studies were published in two peer-reviewed international journals, signaling early academic validation and international interest.
Published pilot study results in peer-reviewed journals
Clinical Evidence in End-Stage Renal Disease in Cats
KIDNIOME, designed to support cats suffering from chronic and end-stage kidney disease, demonstrated statistically meaningful improvements in pilot clinical trials conducted at Seoul National University’s College of Veterinary Medicine.
According to AniBiome, the trials showed:
• Up to 46.3% reduction in ammonia levels, a key toxin associated with renal failure
• 27.6% improvement in creatinine levels, a primary renal function marker
Chronic kidney disease is known to affect more than 30% of cats aged 10 years and older, making it one of the most feared and difficult-to-manage feline diseases worldwide. The study results were published in the international veterinary journal Veterinary Integrative Sciences, providing academic credibility to the findings.
AniBiome stated that because its ultimate goal is therapeutic drug approval, the company plans to proceed with larger-scale, drug-standard clinical trials rather than stopping at supplement-level validation.
KIDNIOME (renal support) and PETMUNIOME (immune support)
Immune-Modulating Research in Dogs with Terminal Cancer
The second product, PETMUNIOME, was developed to improve immune function in pets and is formulated as a probiotic-based compound complex using Dendropanax morbifera, a medicinal tree native to southern Korea.
In pilot clinical trials involving dogs with terminal cancer:
• Lymphocyte levels improved by 48.2%, a key immune and cancer-related indicator
• Inflammatory markers decreased by 21.3%
These results were published in the peer-reviewed journal Journal of Applied Biological Chemistry, further reinforcing the scientific foundation of the product.
Korean Medicinal Heritage Meets Modern Therapeutic Development
Dendropanax morbifera, historically referred to in Korea as the “Tree of Emperors,” has recently gained attention in international research for its neuroprotective and immunomodulatory properties. Beyond veterinary applications, the compound is now being actively studied for hard-to-treat neurological conditions, including post-herpetic neuralgia, highlighting its broader pharmaceutical potential.
Clear Positioning: From Adjunct Therapy to Approved Drug
AniBiome emphasized that clinical trials are not legally required for animal health supplements in most markets, and that few companies undertake them voluntarily. Nevertheless, the company has committed to continued clinical research because its products are being developed with drug approval—not supplement sales—as the final objective.
To support upcoming trials, AniBiome is currently seeking participation from:
• Cat owners managing chronic kidney disease
• Dog breeders and owners caring for dogs with cancer
Leadership by Korea’s Leading Veterinary Disease Experts
One of AniBiome’s founding members, Professor Oh Won-seok, an adjunct professor at Seoul National University’s College of Veterinary Medicine, is recognized as one of Korea’s foremost experts in chronic and intractable animal diseases. He is joined by Professors Kim Min-soo, Cho Sung-beom, and Baek Seung-jun, all from Seoul National University, forming a research team rooted in Korea’s highest level of veterinary science.
Currently, PETMUNIOME and KIDNIOME are available through AniBiome’s official online store in Korea, with the company preparing international launches following country-specific regulatory approvals.
Company name: ANIBIOME Co., Ltd.
Contact name: UnSang Chang (CEO)
Email: cus1619@gmail.com
Website: www.anibiome.com
Country: South Korea
